An Open Label, Phase I Study of Copanlisib to Evaluate the Pharmacokinetics, Safety and Tolerability in Chinese Patients With Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 20 Sep 2019
Price : $35 *
At a glance
- Drugs Copanlisib (Primary)
- Indications Non-Hodgkin's lymphoma
- Focus Pharmacokinetics
- Sponsors Bayer
- 17 Jun 2019 Status changed from recruiting to active, no longer recruiting.
- 17 Dec 2018 Planned End Date changed from 3 Sep 2019 to 3 Apr 2020.
- 17 Dec 2018 Planned primary completion date changed from 11 Jun 2019 to 4 Oct 2019.